Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ICML 2017 | Immunotherapy highlights from ICML 2017

David Maloney • 14 Jun 2017
ICML 2017
Non-Hodgkin Lymphoma Antibodies Checkpoint inhibitors

David Maloney, MD, PhD from the Fred Hutchinson Cancer Center, Seattle, WA provides an overview of the immunotherapy highlights from the International Conference on Malignant Lymphoma (ICML) 2017 held in Lugano, Switzerland. Dr Maloney describes the latest data presented on immunotherapy treatments in lymphoma, including CAR-T cell therapy and checkpoint inhibitor antibodies. Explaining the advances in the field of immunotherapy as well as the challenges, Dr Maloney discusses the approval of future novel treatments. With regards to the impact on patients, Dr Maloney assesses the risk to benefit ratio for patients receiving immunotherapy.

More from David Maloney

Expanding the CAR platform in NHL
David Maloney et al. • 17 Oct 2023
14:23
Highlights from Day 2: addressing challenges in CAR-T therapy for ALL, AML, CLL & more…
David Maloney et al. • 30 Apr 2022
10:21
Advances in CAR-T therapy for lymphoma
Caron Jacobson et al. • 1 May 2022
4:36
Highlights from the immunotherapy in CLL session
David Maloney • 20 Sep 2021

Related Videos

3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
2:11
The role of CAR-T therapy for lymphoma in 2024: expert session highlights
Sridhar Chaganti • 16 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
1:37
Exciting CAR-T clinical trials in LBCL and FL
Gloria Iacoboni • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals